Gelexir Healthcare is a spin-out company formed following early-stage involvement by MIMIT.
The company has developed a novel microgel for the treatment of Degenerative Disc Disease, which addresses the issue at an early stage, before the onset of irreversible disc degeneration of both the nucleus pulposus and annulus fibrosis material.
Founded by Professor Tony Freemont and Brian Saunders, of The University of Manchester’s Schools of Medicine and Materials respectively, Gelexir Healthcare leveraged £215,000 in EPSRC funding and received proof-of-principle funding from UMIP.
It has been granted a patent and is currently completing proof-of-concept experiments and pre-clinical trials before taking the produce to market.
Find out more: http://gelexir-healthcare.co.uk/Roche and Hitachi case studies to come